PRADAXA 150 MG CAPSULE

What it is

PRADAXA 150 MG CAPSULE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as dabigatran etexilate mesylate, under the trade name “Pradaxa”.

FDA gives its dosage form as capsule and its route as oral.

The labeler, the company named on the label, is Boehringer Ingelheim Pharmaceuticals Inc.

FDA’s Established Pharmacologic Class for it is Direct Thrombin Inhibitor.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $94.79 for 30 capsules (30 × $3.1597 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

NADAC also lists, on the row of its brand NDCs, what pharmacies pay for the generic equivalent, a different product: $0.79456 per EA filed.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What NADAC measures · Why 30 capsules · NADAC explanation codes

All 2 NDCs

• 00597-0360-55 · Boehringer Ingelheim Pharmaceuticals Inc. · $3.1597 per EA · eff. 2026-09-23 filed
• 00597-0360-82 · Boehringer Ingelheim Pharmaceuticals Inc. · $3.1597 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

2 other products in the NADAC file share the FDA nonproprietary name dabigatran etexilate mesylate with PRADAXA 150 MG CAPSULE.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-07-22, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $3.1597 per EA filed.

Of the 5 other products in FDA’s Direct Thrombin Inhibitor class priced per EA, 2 have a higher middle NADAC price and 3 a lower one. The one in the middle is DABIGATRAN ETEXILATE 110 MG CP, at $0.93752 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $54.59 for 30 capsules, at an average of $1.81972 per EA in 2024 (2024-01-01 to 2024-12-31) for “Pradaxa” and “Dabigatran Etexilate Mesylate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 481,836 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 capsules? Is it lower than what I would pay through my insurance?
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.